Literature DB >> 16155019

Molecular pathogenesis of diffuse large B-cell lymphoma.

Izidore S Lossos1.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous clinicopathologic entity accounting for 30% of non-Hodgkin's lymphomas. The pathogenesis of DLBCL is complex and heterogeneous. Recent studies using analysis of global gene expression with DNA microarrays and the classical molecular approaches demonstrate presence of several DLBCL subtypes characterized by different cells of origin, cytogenetic and molecular aberrations, and distinct pathogenesis. This review summarizes the progress in understanding of DLBCL biology and presents a state-of-the-art overview of DLBCL molecular pathogenesis.

Entities:  

Mesh:

Year:  2005        PMID: 16155019     DOI: 10.1200/JCO.2005.05.012

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  42 in total

1.  DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status.

Authors:  B L Pike; T C Greiner; X Wang; D D Weisenburger; Y-H Hsu; G Renaud; T G Wolfsberg; M Kim; D J Weisenberger; K D Siegmund; W Ye; S Groshen; R Mehrian-Shai; J Delabie; W C Chan; P W Laird; J G Hacia
Journal:  Leukemia       Date:  2008-02-21       Impact factor: 11.528

2.  The utility of t(14;18) in understanding risk factors for non-Hodgkin lymphoma.

Authors:  Brian C-H Chiu; Qing Lan; Bhavana J Dave; Aaron Blair; Shelia Hoar Zahm; Dennis D Weisenburger
Journal:  J Natl Cancer Inst Monogr       Date:  2008

3.  The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.

Authors:  J-P Jais; C Haioun; T J Molina; D S Rickman; A de Reynies; F Berger; C Gisselbrecht; J Brière; F Reyes; P Gaulard; P Feugier; E Labouyrie; H Tilly; C Bastard; B Coiffier; G Salles; K Leroy
Journal:  Leukemia       Date:  2008-07-10       Impact factor: 11.528

4.  Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.

Authors:  Thomas M Habermann; Sophia S Wang; Matthew J Maurer; Lindsay M Morton; Charles F Lynch; Stephen M Ansell; Patricia Hartge; Richard K Severson; Nathaniel Rothman; Scott Davis; Susan M Geyer; Wendy Cozen; Stephen J Chanock; James R Cerhan
Journal:  Blood       Date:  2008-07-16       Impact factor: 22.113

5.  Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.

Authors:  Ana Borovecki; Petra Korać; Marin Nola; Davor Ivanković; Branimir Jaksić; Mara Dominis
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

6.  Diffuse large B-cell lymphoma recurrence presenting as multiple, progressive cranial neuropathies.

Authors:  Abby R Goron; Stephen Devlin; Stacy Schwartz
Journal:  BMJ Case Rep       Date:  2019-07-19

7.  LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.

Authors:  Wei Peng; Jianzhong Wu; Jifeng Feng
Journal:  Clin Exp Med       Date:  2015-10-16       Impact factor: 3.984

8.  [Extranodal diffuse large B-cell lymphoma--an organotypic disease?].

Authors:  G Ott; A Rosenwald
Journal:  Pathologe       Date:  2007-02       Impact factor: 1.011

9.  Pathophysiology and molecular aspects of diffuse large B-cell lymphoma.

Authors:  Gisele Rodrigues Gouveia; Sheila Aparecida Coelho Siqueira; Juliana Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 10.  Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome.

Authors:  Izidore S Lossos
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.